Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
MYND104
Prospective, Multicenter Non-randomised, Open-label Study Evaluating the Correlation Between Physiological Data Measured by a Portable Sensor and Psychometric Assessment
1 other identifier
interventional
200
1 country
11
Brief Summary
To evaluate, over a period of six months, the links between physiological data collected such as electrodermal activity (or Galvanic Skin Response), motor activity measured by accelerometer, heartbeat measured by photoplestimograph and the clinical evaluation performed by the physician, in patients suffering from major depression disorder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable major-depressive-disorder
Started Sep 2017
Longer than P75 for not_applicable major-depressive-disorder
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 5, 2017
CompletedFirst Submitted
Initial submission to the registry
July 1, 2022
CompletedFirst Posted
Study publicly available on registry
September 21, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedMarch 5, 2024
March 1, 2024
7.8 years
July 1, 2022
March 4, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Comparison of change in MADRS ( Montgomery-Asberg Depression Rating Scale) total score with physiological measurements.
* Change in central rater Montgomery-Asberg Depression Rating Scale (MADRS) total score and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 (low severity of depressive symptoms) and 60 points (high severity of depressive symptoms), higher score indicating poorer health outcomes. The MADRS provides a measure of the overall level of depression.
Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6
Comparison of change in HAD (Hospital Anxiety and Depression) total score with physiological measurements.
* Change in Hospital Anxiety and Depression total score and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Hospital Anxiety and Depression Scale used for measuring anxiety Scored on a scale of 0-21 (higher score more anxiety) and for measuring depression Scored on a scale of 0-21 (higher score more depression).
Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6
Comparison of change in CGI (Clinical Global Impression) scale with physiological measurements.
* Change in CGI scale and comparison with changes in physiological measurements such as activity, emotional arousal, heart rate, heart rate variability, breathing rate and sleep. * The Clinical Global Impression Scale (CGI-s), is a widely administered clinician rated scale that assesses the subject overall illness severity and the degree of improvement from the initial assessment. Illness severity is rated on a 1-7 scale where 1 corresponds to "Normal, Not at All Ill", 2 is "Borderline Mentally Ill", the anchor for 3 is "Mildly Ill", the anchor for 4 is "Moderately Ill", 5 is "Markedly Ill", 6 is "Severely Ill", and 7 is "Among the Most Extremely Ill Patients".The degree of improvement is rated on a 1-7 scale where 1 corresponds to "Very Much Improved", 2 is "Much Improved", the anchor for 3 is "Minimally Improved", the anchor for 4 is "No Change", 5 is "Minimally Worse", 6 is "Much Worse", and 7 is "Very Much Worse".
Baseline, Month1, Month 2, Month 3, Month 4, Month 5, Month 6
Study Arms (1)
Wearable monitor collected phydiological measurements
EXPERIMENTALThis is a single arm study with a wearable monitor that collects physiological measures (falling in the categories physical activity, heart rate, heart rate variability, breathing rate and sleep) 24/7 in ambulatory.
Interventions
All patients who agree to participate in the study are diagnosed by their GP/Psychiatrist with a diagnostic assessment instrument called DSM-5. Participants visit their GPs/Psychiatrists at baseline, month 1, month 2, month 3, month 4, month 5 and month 6. At each visit, the GPs/Psychiatrists: * assess the depression severity by using MADRS scale * assess the severity of illness at time of assessment compared with start of treatment by using CGI-S measures * the patient complete the self-administered questionnaire of HAD scale that measures the symptoms of anxiety and depression.
Eligibility Criteria
You may qualify if:
- Patient able to give written informed consent, - Presenting a major depressive episode defined according to DSM V criteria, - Presenting a MADRS score ≥ 20 - Able to understand all study procedures and follow-up
You may not qualify if:
- \- Inability to wear the wearable monitor for the duration of the study (6 months)
- Patient with a severe medical condition at the discretion of the investigator (neurological, rheumatological, etc.)
- Resistant depression
- Chronic depression, dysthymia
- Depression with psychotic features not congruent with mood, schizophrenia disorder
- Depression with catatonic features
- Substance use disorder in the last 6 months
- Extreme sports during the conduct of the study
- Pre-existing skin infection at the wearable monitor site
- Pregnant or lactating woman
- Participation in another drug or medical device study
- Inability to give informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
135 rue Nestor Longue Epee
Bersée, 59235, France
203 rue de la Motte
Bersée, 59235, France
APPT 22 Residence les Tilleuls
Dax, 40100, France
2 boulevard Winston Churchill
Dijon, 21000., France
2 boulevard Winston Churchill
Dijon, 21000, France
Clinique Lyon Lumiere
Meyzieu, 69330, France
22 rue Jacques Boutrolles
Mont-Saint-Aignan, 76130, France
19 rue de la Liberté
Nice, 06000, France
119 rue de la Pompe
Paris, 75016, France
91 rue Caulaincpurt
Paris, 75018, France
145 avenue des Minimes
Toulouse, 31200, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 1, 2022
First Posted
September 21, 2022
Study Start
September 5, 2017
Primary Completion
June 30, 2025
Study Completion
June 30, 2025
Last Updated
March 5, 2024
Record last verified: 2024-03